Insider Trading Alert - REGN, MA, USB, LUV And AWAY Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Jan. 29, 2014, 48 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $2,167.07 to $320,146,398.72.

Highlighted Stocks Traded by Insiders:

Regeneron Pharmaceuticals (REGN) - FREE Research Report

Sanofi who is 10% Owner at Regeneron Pharmaceuticals bought 157,920 shares at $275.90 on Jan. 29, 2014. Following this transaction, the 10% Owner owned 16.0 million shares meaning that the stake was reduced by 1% with the 157,920-share transaction.

The shares most recently traded at $293.16, up $17.26, or 5.89% since the insider transaction. Historical insider transactions for Regeneron Pharmaceuticals go as follows:

  • 4-Week # shares sold: 4,000
  • 12-Week # shares sold: 13,000
  • 24-Week # shares sold: 19,000

The average volume for Regeneron Pharmaceuticals has been 835,900 shares per day over the past 30 days. Regeneron Pharmaceuticals has a market cap of $27.1 billion and is part of the health care sector and drugs industry. Shares are up 2.29% year-to-date as of the close of trading on Wednesday.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. The company has a P/E ratio of 39.0. Currently there are 10 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on REGN - FREE

TheStreet Quant Ratings rates Regeneron Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income and feeble growth in the company's earnings per share. Get the full Regeneron Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

MasterCard Incorporated (MA) - FREE Research Report

MasterCard Foundation who is 10% Owner at MasterCard Incorporated sold 404,760 shares at $77.74 on Jan. 29, 2014. Following this transaction, the 10% Owner owned 120.0 million shares meaning that the stake was reduced by 0.34% with the 404,760-share transaction.

The shares most recently traded at $79.20, up $1.46, or 1.84% since the insider transaction. Historical insider transactions for MasterCard Incorporated go as follows:

  • 4-Week # shares sold: 431,744
  • 12-Week # shares sold: 433,114
  • 24-Week # shares sold: 434,614

The average volume for MasterCard Incorporated has been 6.9 million shares per day over the past 30 days. MasterCard Incorporated has a market cap of $91.3 billion and is part of the financial sector and financial services industry. Shares are down 7% year-to-date as of the close of trading on Wednesday.

MasterCard Incorporated, together with its subsidiaries, provides transaction processing and other payment-related services in the United States and internationally. The stock currently has a dividend yield of 0.56%. The company has a P/E ratio of 31.2. Currently there are 17 analysts that rate MasterCard Incorporated a buy, no analysts rate it a sell, and 9 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MA - FREE

TheStreet Quant Ratings rates MasterCard Incorporated as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, increase in net income, expanding profit margins and good cash flow from operations. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full MasterCard Incorporated Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

U.S. Bancorp (USB) - FREE Research Report

Dolan Terrance R who is Vice Chairman at U.S. Bancorp sold 7,500 shares at $40.12 on Jan. 29, 2014. Following this transaction, the Vice Chairman owned 31,492 shares meaning that the stake was reduced by 19.23% with the 7,500-share transaction.

The shares most recently traded at $39.85, down $0.27, or 0.68% since the insider transaction. Historical insider transactions for U.S. Bancorp go as follows:

  • 4-Week # shares bought: 10,250
  • 4-Week # shares sold: 158,500
  • 12-Week # shares bought: 10,250
  • 12-Week # shares sold: 158,500
  • 24-Week # shares bought: 10,250
  • 24-Week # shares sold: 159,423

The average volume for U.S. Bancorp has been 8.1 million shares per day over the past 30 days. U.S. Bancorp has a market cap of $74.0 billion and is part of the financial sector and banking industry. Shares are down 1.58% year-to-date as of the close of trading on Wednesday.

U.S. Bancorp, a financial services holding company, provides a range of financial services in the United States. Its services include lending and depository services, cash management, capital market, and trust and investment management services. The stock currently has a dividend yield of 2.27%. The company has a P/E ratio of 13.5. Currently there are 9 analysts that rate U.S. Bancorp a buy, 2 analysts rate it a sell, and 12 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on USB - FREE

TheStreet Quant Ratings rates U.S. Bancorp as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, expanding profit margins and increase in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full U.S. Bancorp Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Southwest Airlines (LUV) - FREE Research Report

Ricks Ron who is EVP, Chief Legal & Reg. Off. at Southwest Airlines sold 35,000 shares at $20.81 on Jan. 29, 2014. Following this transaction, the EVP, Chief Legal & Reg. Off. owned 343,335 shares meaning that the stake was reduced by 9.25% with the 35,000-share transaction.

The shares most recently traded at $21.14, up $0.33, or 1.57% since the insider transaction. Historical insider transactions for Southwest Airlines go as follows:

  • 4-Week # shares sold: 13,400
  • 12-Week # shares sold: 15,400
  • 24-Week # shares sold: 154,563

The average volume for Southwest Airlines has been 7.4 million shares per day over the past 30 days. Southwest Airlines has a market cap of $14.8 billion and is part of the services sector and transportation industry. Shares are up 13.11% year-to-date as of the close of trading on Wednesday.

Southwest Airlines Co. operates passenger airlines that provide scheduled air transportation services in the United States. As of December 31, 2012, the company operated 694 aircraft, including 606 Boeing 737 aircraft and 88 Boeing 717 aircraft. The stock currently has a dividend yield of 0.75%. The company has a P/E ratio of 19.0. Currently there are 8 analysts that rate Southwest Airlines a buy, 2 analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on LUV - FREE

TheStreet Quant Ratings rates Southwest Airlines as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and good cash flow from operations. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Southwest Airlines Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

HomeAway (AWAY) - FREE Research Report

Sharples Brian who is President and CEO at HomeAway sold 111,072 shares at $40.09 on Jan. 29, 2014. Following this transaction, the President and CEO owned 72,153 shares meaning that the stake was reduced by 60.62% with the 111,072-share transaction.

The shares most recently traded at $40.57, up $0.48, or 1.19% since the insider transaction. Historical insider transactions for HomeAway go as follows:

  • 4-Week # shares sold: 3,125
  • 12-Week # shares sold: 72,728
  • 24-Week # shares sold: 119,058

The average volume for HomeAway has been 1.6 million shares per day over the past 30 days. HomeAway has a market cap of $3.7 billion and is part of the technology sector and internet industry. Shares are down 0.64% year-to-date as of the close of trading on Wednesday.

HomeAway, Inc., together with its subsidiaries, operates an online marketplace for the vacation rental industry worldwide. Its vacation rental properties include homes, condominiums, villas, and cabins to the public on a nightly, weekly, or monthly basis. The company has a P/E ratio of 145.1. Currently there are 8 analysts that rate HomeAway a buy, 1 analyst rates it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AWAY - FREE

TheStreet Quant Ratings rates HomeAway as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we find that the growth in the company's net income has been quite unimpressive. Get the full HomeAway Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

Stocks Waver Amid a Rise in Bond Yields, Strong Earnings

Stocks Waver Amid a Rise in Bond Yields, Strong Earnings

Investors Shouldn't Be Worried About Trump's Trade Tariffs: Ian Bremmer

Investors Shouldn't Be Worried About Trump's Trade Tariffs: Ian Bremmer

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists

NYSE Suspends Trading for Some Shares of Nasdaq-Listed Amazon, Alphabet

NYSE Suspends Trading for Some Shares of Nasdaq-Listed Amazon, Alphabet

Video: Jim Cramer Reveals Why He's Cautious on Stocks

Video: Jim Cramer Reveals Why He's Cautious on Stocks